HistologiThe European postmarketing adult Osteosarcoma Surveillance Study: Characteristics of patients A preliminary report

Acta Orthopaedica

Volumn 80, Issue SUPPL. 334, 2009, Pages 67-74

  Von Schéele, Birgitta ^a   Martin, Rebecca D ^a   Gilsenan, Alicia W ^a   Ceberg, Jeanette ^b   Andrews, Elizabeth B ^a   Masica, Daniel ^c   Alvegård, Thor ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b LUND UNIVERSITY   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CORTICOSTEROID; ESTROGEN; PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BONE INFECTION; BONE INJURY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DRUG SURVEILLANCE PROGRAM; ENVIRONMENTAL EXPOSURE; FAMILY HISTORY; FEMALE; FINLAND; GEOGRAPHIC DISTRIBUTION; HUMAN; ICELAND; MALE; NORWAY; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; SWEDEN; TUMOR LOCALIZATION;

EID: 73349115514     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/17453670902805064     Document Type: Article

References (13)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995; 75(1 Suppl): 203-210
2. International Agency for Research on Cancer (IARC). Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours. Edited by C D M Fletcher, K Unni and F Mertens. 2002; pp 227-228 Available from http://www.iarc.fr/en/Publications/PDFs-online/ Cancer-Pathology-and-Genetics/World-Health-Organization-Classification-of- Tumours2.
3. Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, Dominkus M, Saeter G, Bauer H, Meller I, Szendroi M, Folleras G, San-Julian M, van der Eijken J.Osteosarcoma over the age of forty. Eur J Cancer 2003; 39(2): 157-163
4. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 2008; 6(1): 12-16
5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-1441
6. Ries LAG, Wingo PA, Miller DS, Howe HA, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colonrectal cancer. Cancer 2000: 88; 2398-2424
7. Smeland S, Wiebe T, Böhling T, Brosjö O, Jonsson K, Alvegård TA. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 2004; 75(S 311): 92-98
8. Socialstyrelsen. Cancer incidence in Sweden 2006. Statistics: health and diseases 2007:16 series. 2007 Dec 19. Available from http://www.socialstyrelsen. se/NR/rdonlyres/AAD7CA00-CCE3-4E3E-B998-1450BD7FB4A1/9428/20074216.pdf
9. Stark A, Kreicbergs A, Nilsonne U, Silfverswärd C. The age of osteosarcoma patients is increasing. An epidemiological study of osteosarcoma in Sweden 1971 to 1984. J Bone Joint Surg Br 1990; 72 (1): 89-93.
10. Unni KK, Dahlin DC. Dahlin's bone tumor: general aspects and data on 11,087 cases. Lippincott-Raven, Philadelphia 1996; 5: 67-69, 143-144
11. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32 (4): 426-438
12. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-321
13. Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M. 2008. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques following long-term treatment with teriparatide {rhPTH(1-34)}. J Bone Miner Res, Published online August 6, 2008: 10.1359/jbmr.080807.